FDA accepts Crinetics Pharmaceuticals’ NDA for acromegaly treatment therapy
The US Food and Drug Administration (FDA) has accepted Crinetics Pharmaceuticals' paltusotine new drug application (NDA) as a long-term maintenance and potential treatment for acromegaly in the adult population.